Xiao L ZhuBrooklyn, NY

2020027, Aug 27, 2020

Aug 30, 2018

16/642440

- Princeton NJ, US
Muthoni G. Kamau - Lawrenceville NJ, US
Xiao Zhu - Winchester MA, US

C07H 21/02
C07K 16/28

The present invention is directed to compounds of the formulawherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

2020009, Mar 26, 2020

May 10, 2018

16/612076

- Princeton NJ, US
Emily Charlotte CHERNEY - Newtown PA, US
Liping ZHANG - East Windsor NJ, US
Audris HUANG - New Hope PA, US
Weifang SHAN - Princeton NJ, US
David K. WILLIAMS - Delran NJ, US
Xiao ZHU - Winchester MA, US
Weiwei GUO - Chatham Township NJ, US

C07D 403/12
C07D 213/85
C07D 401/12
C07D 471/04

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

2018018, Jul 5, 2018

Jun 23, 2016

15/738362

- Princeton NJ, US
Joseph B. Santella - Springfield PA, US
Venkatram Reddy Paidi - Bangalore, Karnataka, IN
Hong Wu - New Hope PA, US
John V. Duncia - Newtown PA, US
Satheesh Kesavan Nair - Bangalore, Karnataka, IN
John Hynes - Washington Crossing PA, US
Xiao Zhu - Potomac MD, US

C07D 487/04
C07D 471/04

Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 R; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 R; and R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.